Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03381170 · ClinicalTrials.gov registry record · Phase 2
An Extension of the TG1101-RMS201 Trial
A Phase 2 study, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT03381170 is a Phase 2 study that has completed, run by TG Therapeutics. The registered enrollment target is 48 participants.
The verdict
NCT03381170, a Phase 2 study, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Interventions
- BIOLOGICAL Ublituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2022-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03381170
The ClinicalTrials.gov registry entry for NCT03381170 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ublituximab is the first listed.
NCT03381170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03381170 about?
NCT03381170 is a clinical study titled "An Extension of the TG1101-RMS201 Trial". This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
What is the current status of trial NCT03381170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2017-06-01. Estimated completion is 2022-11-11.
What interventions are being tested in trial NCT03381170?
The interventions under investigation include: Ublituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03381170?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.